Boston Scientific is buying Cryterion Medical, owner of an invention that uses a burst of cold to the heart to treat atrial fibrillation, for $200 million. (Evan Ramstad — Bloomberg News/The ...

Boston Scientific Corp. (BSX) on Thursday said it agreed to buy the roughly 65% of Cryterion Medical Inc. it doesn’t already own for $202 million in cash. Cryterion is developing a single-shot ...

Although Cryterion’s technology hasn’t been approved for use in any country, initial clinical trials have shown promise, according to Keegan Harper, president and CEO of Cryterion Medical.

Boston Scientific is acquiring Cryterion Medical, a company the medical device giant has invested in since its launch in 2016, by buying up the remaining 65% stake for $202 million upfront as Bosto ...

Boston Scientific has been an investor in Cryterion since its inception in 2016 and the transaction price for the approximately 65 percent remaining stake not already owned by Boston Scientific ...

Cryterion Medical is a privately held medical device manufacturer developing a single-shot cryoablation platform to treat atrial fibrillation, which is an irregular rapid heart beat usually caused ...

Cryterion Medical is developing a treatment for atrial fibrillation, or irregular heartbeat. Boston Scientific has been an investor in the company since it was launched in 2016.

Boston Scientific Corp. has inked an agreement to acquire the rest of Cryterion Medical Inc. it does not own for $202 million in up-front cash. The attraction of Cryterion, of Carlsbad, Calif., is the ...

Before his time with Cryterion Medical, he served as President and CEO of Bardy Diagnostics, whose novel ECG monitoring system achieved US and European approval under his leadership.